DLX6 and hepatocellular carcinoma: Taken together, extensive amount evidence has shed a lot of light on how inhibiting lncRNA DLX6-AS1 could lead to a reduction in tumorigenesis and cancer development of HCC by inhibiting the self-renewal, amplification, and proliferation of LCSCs.